IKT Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$6.00median target· current $2.50 (+140.0%)9 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-0.450.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$332.1MSmall cap
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 2.10
- P/S (TTM)
- 10.39
- EV/EBITDA
- 0.34
Profitability & growth
- ROE (TTM)
- -52.0%
- Operating margin
- 0.0%
- Revenue growth YoY
- -100.0%
- Dividend yield
- —
- Beta
- 0.95
Last earnings
Aug 11, 2026 · Estimate $-0.09 · Reported $-0.11
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Inhibikase Therapeutics Inc
Company profileInhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside and outside the brain. The company is headquartered in Atlanta, Georgia.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 1000 N. WEST STREET, WILMINGTON, DE
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$332.1M
Shares outstanding$139.5M
52W high$2.54
52W low$1.33
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent